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Background: The impact of chemotherapy-associated liver injury (CALI) on postoperative outcome in
patients undergoing partial hepatectomy for colorectal liver metastases (CRLM) remains controversial.
The objective of this study was to clarify the effect of CALI (sinusoidal dilatation (SD), steatosis and
steatohepatitis) on postoperative morbidity and mortality by investigating a large data set from multiple
international centres.
Methods: PubMed and Embase were searched for studies published between 1 January 2004 and 31
December 2013 with keywords ‘chemotherapy’, ‘liver resection’, ‘outcome’ and ‘colorectal metastases’
to identify potential collaborating centres. Univariable and multivariable analyses were performed using
binary logistic regression models, with results presented as odds ratios (ORs) with 95 per cent confidence
intervals.
Results: A consolidated database comprising 788 patients who underwent hepatectomy for CRLM in
eight centres was obtained. In multivariable analyses, severe SD was associated with increased major
morbidity (Dindo–Clavien grade III–V; OR 1⋅73, 95 per cent c.i. 1⋅02 to 2⋅95; P = 0⋅043). Severe steatosis
was associated with decreased liver surgery-specific complications (OR 0⋅52, 95 per cent c.i. 0⋅27 to 1⋅00;
P = 0⋅049), whereas steatohepatitis was linked to an increase in these complications (OR 2⋅08, 1⋅18 to 3⋅66;
P = 0⋅012). Subgroup analysis showed that lobular inflammation was the sole component associated with
increased overall morbidity (OR 2⋅22, 1⋅48 to 3⋅34; P = 0⋅001) and liver surgery-specific complications
(OR 3⋅35, 2⋅11 to 5⋅32; P < 0⋅001). Finally, oxaliplatin treatment was linked to severe SD (OR 2⋅74, 1⋅67
to 4⋅49; P < 0⋅001).
Conclusion: An increase in postoperative major morbidity and liver surgery-specific complications was
observed after partial hepatectomy in patients with severe SD and steatohepatitis. Postoperative liver
failure occurred more often in patients with severe SD.
© 2017 BJS Society Ltd BJS 2017; 104: 990–1002
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Introduction
Colorectal cancer is the third most common cancer world-
wide, affecting over 1⋅3 million patients annually1. Approx-
imately 50 per cent of these patients develop colorectal liver
metastases (CRLM)2,3. Although liver resection provides
the best prospect of cure, only 10–30 per cent of patients
with liver metastases are eligible for hepatic surgery3,4. For
patients with tumours deemed unresectable, neoadjuvant
systemic chemotherapy can prolong survival, and poten-
tially allow future hepatic resection2,5.
For decades, 5-fluorouracil (5-FU) was the sole option
for treating CRLM. This has changed markedly in the new
millennium; with the approval of irinotecan, oxaliplatin and
humanized monoclonal antibodies, approximately 15 per
cent of patients with initially unresectable tumours became
eligible for liver resection6,7. Unfortunately, administration
of irinotecan- and/or oxaliplatin-based chemotherapeutic
agents has been associated with a harmful side-effect in the
form of liver injury8,9.
Chemotherapy-associated liver injury (CALI) is often
reported in patients with CRLM, and appears to be
regimen-specific. For instance, oxaliplatin treatment is
associated with sinusoidal obstruction syndrome (SOS)10,
and linked to increased occurrence of nodular regenerative
hyperplasia (NRH)11. Co-administration of bevacizumab
with oxaliplatin, however, has been reported to be associ-
ated with a decrease in both the incidence and severity of
SOS and NRH10–12. Irinotecan-based regimens appear
to be related to the development of steatohepatitis8,13,14.
Importantly, because patients commonly receive several
chemotherapeutic agents to offer optimal benefit in down-
sizing tumours, it is difficult to identify the specific agents
responsible for injury to the hepatic parenchyma.
Certain studies9,13,15–18 have claimed a negative cor-
relation between CALI and postoperative outcome
(postoperative morbidity, mortality), but others19–23 could
not reproduce this. Therefore, it remains unclear whether
CALI influences postoperative morbidity and mortality.
The aim of the present study was to explore whether
sinusoidal dilatation (SD), steatosis and steatohepatitis are
associated with increased morbidity and mortality rates
after partial hepatectomy by performing a meta-analysis of
individual participant data based on a systematic literature
review. Additionally, factors associated with the occurrence
of CALI were identified.
Methods
An extensive protocol, written before the start of this study,
can be found in Appendix S1 (supporting information).
PRISMA and MOOSE guidelines were followed when
conducting and reporting this review24,25.
Search strategy for identification of studies
Systematic searches were performed in MEDLINE
(PubMed) and Embase for studies published between 1
January 2004 and 31 December 2013 using a search matrix
including the following four categories: liver resection,
chemotherapy, tumour type and outcome. For the pur-
pose of performing a more comprehensive search, the
type of liver injury was not included in the search matrix.
The full search strategy is shown in Table S1 (supporting
information). The first publication date was fixed at 2004
because the widely used criteria for scoring SD, steatosis
and steatohepatitis were developed in 200426 and 200527.
No language filter was applied.
Inclusion criteria
Studies meeting the following criteria were considered
eligible for inclusion: adult patients (aged over 18 years),
who underwent liver resection for CRLM, with descrip-
tion of postoperative short-term overall morbidity, liver
surgery-specific complications, postoperative liver fail-
ure or overall mortality (within 90 days or in-hospital)
after liver resection, and with pathological assessment of
non-tumorous liver specimens for SD, steatosis and/or
steatohepatitis (Table S2, supporting information). Studies
with patients who received preoperative hepatic arterial
infusion of chemotherapy were excluded, as were case
reports, comments, those with published abstracts only,
editorials and reviews.
Study identification and data collection
Duplicates were removed. Two authors independently
screened all titles and abstracts and excluded those not per-
tinent to the review. Any discrepancy was resolved by con-
sensus. The remaining articles were included for full-text
revision and assessed independently for eligibility by the
two authors. Reference lists of fully reviewed articles were
checked manually for additional potential citations, along
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with exploration of a personal library that was established
during previous research on this topic28,29.
Definitions
SD was graded according to Rubbia-Brandt and
colleagues26, with grade 2–3 (severe SD) considered
clinically relevant as it reflects rupture of sinusoidal
wall integrity. SD is one of the most important his-
tological features of SOS, and its severity is generally
accepted to correspond to the severity of SOS. Steato-
sis and steatohepatitis were graded according to the
system of Kleiner et al.27. Severe steatosis was defined
as more than 33 per cent of parenchyma affected by
steatosis27. A non-alcoholic steatohepatitis activity score
(NAS) of 4 or more was considered as steatohepatitis
to provide a working cut-off value conforming with
the literature30. CALI was defined as any occurrence
of severe SD, severe steatosis or steatohepatitis. Co-
morbidity was defined as any disease affecting the patient
apart from CRLM (diabetes mellitus, pulmonary, renal,
cardiovascular and other diseases). Overall morbidity was
defined as any complication occurring within 90 days
after surgery or during the hospital stay, and graded
according to the classification of Dindo and colleagues31.
Major morbidity was defined as Dindo–Clavien
grade III (requiring invasive intervention) or higher.
The concept of a liver surgery-specific complication
was analogous to the liver surgery-specific composite
endpoint developed in 2011, and included one or more of
the following events: ascites, postoperative liver failure,
bile leakage, intra-abdominal abscess, intra-abdominal
haemorrhage and operative mortality32. Postoperative
liver failure was defined as the concurrent presence of a
prothrombin time below 50 per cent and a serum bilirubin
level greater than 50 μmol/l (the 50–50 criteria) on or after
postoperative day 533. Postoperative mortality included
death from any cause within 90 days after surgery or during
the hospital admission. Major hepatectomy was defined as
resection of three or more Couinaud liver segments34.
Risk-of-bias assessment
The risk of bias of the final included studies was assessed
independently by two blinded researchers using the Qual-
ity in Prognosis Studies (QUIPS) tool35,36. Discrepancies
were discussed by the two authors and consensus was
reached. The QUIPS tool includes six bias domains:
participation, attrition, prognostic factor measurement,
confounding measurement and account, outcome mea-
surement, and analysis and reporting. The results of
assessment of each of the six domains were taken together
to calculate an overall low, moderate or high risk of bias,
as follows: overall low risk of bias, two or fewer domains
rated as moderate risk and the remaining domains as low
risk; overall moderate risk, at least three domains rated as
moderate risk and the remaining domains as low risk; and
high overall risk, one or more domains rated as high risk,
independent of the rating of the remaining domains.
Data handling and statistical analysis
Corresponding authors from studies that fulfilled the inclu-
sion criteria were contacted by e-mail for collaboration
and sharing of coded data (by numbering) for the pub-
lished cohort. Each author was asked to sign a specific data
transfer agreement form, which assured careful handling
of the data. Coded data were arranged in a preconstructed
Excel™ file (Microsoft, Redmond, Washington, USA) and
subsequently imported into SPSS® for Windows® version
20.0 (IBM, Armonk, New York, USA).
Patient characteristics were compared using the Stu-
dent’s t test for numerical variables. For categorical
variables, the Pearson χ2 test with continuity correction
was applied, or Fisher’s exact test when any of the expected
values was smaller than five. The influence of preoperative
chemotherapeutic agents on liver injury, and subsequently
the effect of liver injury on short-term postoperative out-
come, were analysed by applying one-step binary logistic
regression models. Individual participant data from all
studies were pooled and modelled simultaneously. This
approach was considered more optimal because each
study showed relatively few events per outcome and small
sample sizes, and the one-step approach for pooled data
allowed the exact binomial distribution to be used and did
not require continuity corrections when there were no
events37,38. For missing values, multiple imputations were
performed, assuming that data were missing at random.
The number of imputations was determined by the max-
imum percentage of missing data in the data set. In this
study, 30 imputations were performed, as the maximum
amount of missing data was 26 per cent (minor/major
morbidity). Variables in multiple imputations are listed
in Table S3 (supporting information). A complete-case
sensitivity analysis was also conducted. Clustering of
patients from different studies was integrated as a sepa-
rate co-variable (‘database source’) and included in binary
logistic regression models in every analysis38. A single vari-
able together with database source created the univariable
model. All variables with P ≤ 0⋅200 in univariable analysis
were included in the multivariable analysis. In addition,
database source and variables known to be related to the
outcome (either well described in literature or based on
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Titles and abstracts screened for potential
relevance n = 1191
Studies with authors contacted n = 32 
Articles identified by database search n = 1473
    PubMed  n = 997
    Embase n = 476
Full-text articles screened for potential inclusion
(including articles obtained from reference checking
and personal library) n = 98
Studies with authors agreeing to share
original data n = 8 
Final consolidated database n = 788 patients
Consolidated database n = 816 patients
Excluded n = 28
 PH for other tumours n = 8
  Benign tumours n = 2
  HCC n = 1
  CCA or gallbladder carcinoma n = 1
  Other metastases n = 4
 PH for unknown indication n = 20
Excluded n = 66
     In vitro study n = 1
 Review n = 2
 Case report n = 6
 Information on tumour type or preoperative CTx unclear n = 3
 SD not defined according to Rubbia-Brandt et al.26 n = 1
 Did not score steatosis, SD or steatohepatitis n = 37
 Difference in postoperative outcome between patients with
   and without CALI not investigated n = 10
 Postoperative outcome not investigated n = 6
Excluded on basis of title or abstract
n = 1093
Manual and automatic removal of
duplicates n = 282
Fig. 1 Flow chart showing selection of articles for review. CTx, chemotherapy; SD, sinusoidal dilatation; CALI,
chemotherapy-associated liver injury; PH, partial hepatectomy; HCC, hepatocellular carcinoma; CCA, cholangiocarcinoma
careful discussion and consensus between the authors)
were forced into the multivariable model.
A subgroup analysis including only patients who received
oxaliplatin-based treatment was performed to investigate
the impact of bevacizumab on the occurrence of severe
SD. At a later stage of the study, data to investigate
the influence of separate NAS subcategories (steatosis,
lobular inflammation and hepatocellular ballooning) on
postoperative outcome were requested. A subgroup anal-
ysis including cohorts with available data on NAS sub-
categories was undertaken. The methods of analysis of
these data were identical to those described above. Unad-
justed and adjusted odds ratios (ORs) with 95 per cent con-
fidence intervals were calculated. P ≤ 0⋅050 was considered
significant for all analyses.
Results
The search strategy resulted in 1191 unique hits (Fig. 1).
In total, 1093 articles were excluded on the basis of title or
abstract, and the remaining 98 articles were subjected to
full-text evaluation. Thirty-two studies met the inclusion
criteria and the 30 corresponding authors were contacted
by e-mail. Nineteen responded, of whom eight agreed to
share their raw data. Other authors could not be contacted
(Fig. S1, supporting information). Potential publication
bias was excluded by testing for asymmetry in a funnel
plot. The eight included studies16,17,39–44 were assessed
for risk of bias using the QUIPS tool. Overall ratings are
shown in Table 1. Six articles showed an overall low risk
of bias and one study each had a moderate or high risk.
Detailed scoring can be found in Table S4 (supporting
information). Because the individual participant data from
all studies were pooled and modelled simultaneously, an
overall rating was also calculated without taking the study
confounding and statistical analysis domains into account;
all studies then showed a low risk of bias based on the
remaining four domains.
Characteristics of the included studies are summarized in
Table 1. The consolidated cohort consisted of 816 patients
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Table 1 Characteristics of studies included in final database
Reference Country
Study
type Population*
QUIPS
score Comparisons Key findings
Gómez-Ramírez
et al.39
Spain PCS 45 (46) Low Neoadjuvant CTx versus
no CTx
Patients treated with oxaliplatin
had a higher incidence of SOS,
an increase in liver
complications and longer mean
hospital stay
Nam et al.40 Korea RCS 89 Low Oxaliplatin CTx versus
non-oxaliplatin CTx
Sinusoidal injury is frequently seen
in oxaliplatin-treated livers and
should be documented in
surgical pathology practice
when extensive
Pessaux et al.41 France RCC 52 (36) High Neoadjuvant CTx versus
CTx+
cetuximab/bevacizumab
The addition of bevacizumab or
cetuximab to the neoadjuvant
CTx does not increase
morbidity rates after
hepatectomy for CRLM
Pilgrim et al.16 Australia RCS 232 Low Severe versus non-severe
CALI
Severe steatosis was associated
with increased postoperative
morbidity, whereas severe
steatohepatitis and sinusoidal
injury were not
Soubrane et al.42 France RCS 78 (105) Low Severe versus non-severe
SD
SOS 2–3 was associated with
postoperative hepatic
dysfunction and ascites after
major liver resection
Takamoto et al.43 Japan RCS 55 (104) Moderate Liver injury versus no liver
injury
Hepatic functional reserve,
represented by the ICG-R15
value, improves during the
period after cessation of
chemotherapy
van der Pool et al.44 The Netherlands RCS 104 Low Neoadjuvant CTx versus
CTx+bevacizumab
Bevacizumab added to
oxaliplatin-based CTx may
protect against moderate SD
without significantly influencing
morbidity
Viganò et al.17 Italy PCS 100 Low Severe versus non-severe
CALI
Liver biopsy cannot be considered
a reliable tool in assessing CALI
except for steatosis. Proportion
of liver dysfunction was higher
among patients with CALI
*Values are number of patients in cohort reported in published article, with number in shared database in parentheses. QUIPS, Quality in Prognosis
Studies; PCS, prospective cohort study; CTx, chemotherapy; SOS, sinusoidal obstruction syndrome; RCS, retrospective cohort study; RCC,
retrospective case–control study; CRLM, colorectal liver metastases; CALI, chemotherapy-associated liver injury; SD, sinusoidal dilatation; ICG-R15,
indocyanine green retention rate at 15 min.
(Fig. 1). Twenty-eight patients were excluded because they
underwent surgery for indications other than CRLM,
leaving 788 patients for analysis. Patient characteristics,
surgical details and postoperative outcomes of the con-
solidated cohort are shown in Table 2. There were 453
men (57⋅5 per cent) and 335 women (42⋅5 per cent),
with a median age of 61 (range 25–86) years. SD was
severe in 183 patients (24⋅1 per cent), steatosis was severe
in 117 (15⋅6 per cent) and steatohepatitis in 100 (14⋅5
per cent). Of the 525 patients who received 5-FU, 396
(75⋅4 per cent) had simultaneous treatment with oxali-
platin and 135 (25⋅7 per cent) with irinotecan. Of the 136
patients who received capecitabine, 119 (87⋅5 per cent) had
simultaneous treatment with oxaliplatin. Cetuximab and
bevacizumab were most frequently administered together
with oxaliplatin. All 61 patients who received cetuximab,
and 138 of 164 (84⋅1 per cent) who received bevacizumab,
were co-treated with oxaliplatin. Of 635 patients with NAS
subcategory data, 96 (15⋅1 per cent) had a NAS of 4 or
more. Only three patients (3 per cent) with a NAS of 4 or
higher did not show lobular inflammation. The relation-
ship between NAS and lobular inflammation is summarized
in Table S5 (supporting information).
Sensitivity analysis showed similar results for complete-
case analysis and that with multiple imputation (detailed
information available on request). The influence of severe
SD, severe steatosis, steatohepatitis and other poten-
tial factors related to short-term overall morbidity, liver
© 2017 BJS Society Ltd www.bjs.co.uk BJS 2017; 104: 990–1002
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Table 2 Patient, surgical and postoperative characteristics
Sinusoidal dilatation (n=760) Steatosis (n=752) Steatohepatitis (n= 690)
n
Non-severe
(n=577)
Severe
(n=183) P†
Non-severe
(n=635)
Severe
(n=117) P
NAS<4
(n=590)
NAS≥4
(n=100) P†
Age (years)* 788 61(11) 60(10) 0⋅576‡ 61(11) 60(9) 0⋅527‡ 61(11) 61(10) 0⋅784‡
Sex 0⋅836 1⋅000 0⋅784
M 453 335 (58⋅1) 104 (56⋅8) 366 (57⋅6) 68 (58⋅1) 336 (56⋅9) 59 (59⋅0)
F 335 242 (41⋅9) 79 (43⋅2) 269 (42⋅4) 49 (41⋅9) 254 (43⋅1) 41 (41⋅0)
BMI (kg/m2)* 706 25⋅3(4⋅4) 24⋅4(3⋅9) 0⋅001‡ 24⋅7(4⋅1) 27⋅6(4⋅1) <0⋅001‡ 24⋅9(4⋅2) 26⋅7(3⋅9) < 0⋅001‡
Co-morbidity 0⋅259 0⋅012 0⋅158
No 363 247 (49⋅3) 93 (54⋅7) 290 (52⋅2) 41 (38⋅3) 271 (51⋅4) 31 (42)
Yes 336 254 (50⋅7) 77 (45⋅3) 266 (47⋅8) 66 (61⋅7) 256 (48⋅6) 43 (58)
Preoperative chemotherapy 0⋅001 0⋅032 0⋅198
No 127 110 (19⋅3) 15 (8⋅4) 114 (18⋅2) 11 (9⋅6) 112 (19⋅3) 13 (13)
Yes 649 459 (80⋅7) 164 (91⋅6) 511 (81⋅8) 104 (90⋅4) 468 (80⋅7) 85 (87)
5-FU 0⋅006 0⋅463 0⋅396
No 245 201 (35⋅6) 43 (24⋅2) 210 (34⋅0) 34 (29⋅8) 213 (37⋅0) 31 (32)
Yes 525 363 (64⋅4) 135 (75⋅8) 408 (66⋅0) 80 (70⋅2) 362 (63⋅0) 66 (68)
Capecitabine 0⋅173 0⋅158 0⋅061
No 634 454 (80⋅5) 152 (85⋅4) 511 (82⋅4) 87 (76⋅3) 466 (81⋅0) 70 (72)
Yes 136 110 (19⋅5) 26 (14⋅6) 109 (17⋅6) 27 (23⋅7) 109 (19⋅0) 27 (28)
Irinotecan 0⋅033 0⋅033 1⋅000
No 627 445 (78⋅9) 154 (86⋅5) 508 (81⋅9) 83 (72⋅8) 453 (78⋅8) 77 (79)
Yes 143 119 (21⋅1) 24 (13⋅5) 112 (18⋅1) 31 (27⋅2) 122 (21⋅2) 20 (21)
Bevacizumab 0⋅072 0⋅143 0⋅101
No 605 430 (76⋅4) 148 (83⋅1) 487 (78⋅7) 82 (71⋅9) 444 (77⋅4) 67 (69)
Yes 164 133 (23⋅6) 30 (16⋅9) 132 (21⋅3) 32 (28⋅1) 130 (22⋅6) 30 (31)
Cetuximab 0⋅198 0⋅716 0⋅462
No 708 522 (92⋅7) 159 (89⋅3) 566 (91⋅4) 106 (93⋅0) 522 (90⋅9) 91 (94)
Yes 61 41 (7⋅3) 19 (10⋅7) 53 (8⋅6) 8 (7⋅0) 52 (9⋅1) 6 (6)
Oxaliplatin <0⋅001 0⋅716 0⋅295
No 266 228 (40⋅5) 37 (20⋅8) 226 (36⋅5) 39 (34⋅2) 231 (40⋅2) 33 (34)
Yes 503 335 (59⋅5) 141 (79⋅2) 393 (63⋅5) 75 (65⋅8) 343 (59⋅8) 64 (66)
Resection type <0⋅001 0⋅921 0⋅713
Minor (<3 segments) 398 330 (57⋅2) 67 (36⋅8) 335 (52⋅8) 63 (53⋅8) 339 (57⋅6) 55 (55⋅0)
Major (≥3 segments) 389 247 (42⋅8) 115 (63⋅2) 299 (47⋅2) 54 (46⋅2) 250 (42⋅4) 45 (45⋅0)
PVE 0⋅001 0⋅046 0⋅512
No 623 461 (92⋅0) 140 (82⋅4) 498 (89⋅6) 103 (96⋅3) 491 (93⋅2) 71 (96)
Yes 76 40 (8⋅0) 30 (17⋅6) 58 (10⋅4) 4 (3⋅7) 36 (6⋅8) 3 (4)
Pringle manoeuvre 0⋅018 0⋅974 1⋅000
No 446 347 (64⋅5) 93 (54⋅1) 366 (62⋅1) 71 (62⋅8) 349 (63⋅9) 61 (64)
Yes 291 191 (35⋅5) 79 (45⋅9) 223 (37⋅9) 42 (37⋅2) 197 (36⋅1) 34 (36)
Transfusion of packed RBCs 0⋅004 0⋅871 0⋅382
No 646 492 (86⋅2) 139 (76⋅8) 529 (84⋅4) 100 (85⋅5) 508 (86⋅8) 83 (83⋅0)
Yes 134 79 (13⋅8) 42 (23⋅2) 98 (15⋅6) 17 (14⋅5) 77 (13⋅2) 17 (17⋅0)
Postoperative short-term outcomes
Length of hospital stay (days)* 768 14(13) 15(11) 0⋅240‡ 15(11) 14(17) 0⋅660‡ 14(12) 15(14) 0⋅266‡
Overall morbidity 0⋅009 0⋅935 0⋅024
No 443 339 (59⋅3) 87 (47⋅8) 360 (57⋅3) 66 (56⋅4) 355 (60⋅6) 48 (48⋅0)
Yes 338 233 (40⋅7) 95 (52⋅2) 268 (42⋅7) 51 (43⋅6) 231 (39⋅4) 52 (52⋅0)
None/minor morbidity (DC 0–II) 491 362 (88⋅5) 106 (73⋅1) <0⋅001 397 (85⋅6) 69 (85) 1⋅000 367 (89⋅5) 62 (81) 0⋅041
Major morbidity (DC III–V) 89 47 (11⋅5) 39 (26⋅9) 67 (14⋅4) 12 (15) 43 (10⋅5) 15 (19)
Liver surgery-specific complication <0⋅001 0⋅031 0⋅247
No 598 455 (79⋅8) 121 (66⋅9) 475 (75⋅9) 100 (85⋅5) 470 (80⋅6) 75 (75⋅0)
Yes 180 115 (20⋅2) 60 (33⋅1) 151 (24⋅1) 17 (14⋅5) 113 (19⋅4) 25 (25⋅0)
Mortality 0⋅200§ 1⋅000§ 0⋅422§
No 780 573 (99⋅3) 179 (97⋅8) 628 (98⋅9) 116 (99⋅1) 586 (99⋅3) 98 (98⋅0)
Yes 8 4 (0⋅7) 4 (2⋅2) 7 (1⋅1) 1 (0⋅9) 4 (0⋅7) 2 (2⋅0)
Postoperative liver failure <0⋅001 0⋅302§ 1⋅000§
No 755 563 (98⋅6) 166 (91⋅7) 608 (97⋅0) 116 (99⋅1) 578 (99⋅0) 99 (99⋅0)
Yes 24 8 (1⋅4) 15 (8⋅3) 19 (3⋅0) 1 (0⋅9) 6 (1⋅0) 1 (1⋅0)
Value in parentheses are percentages unless indicated otherwise; *values are mean(s.d.). Data represent original data without multiple imputations; owing
to missing values, some numbers do not add up to the total number of patients. NAS, non-alcoholic fatty liver disease activity score; 5-FU, 5-fluorouracil;
PVE, portal vein embolization; RBC, red blood cell; DC, Dindo–Clavien grade. †Pearson χ2 test with continuity correction, except ‡Student’s t test and
§Fisher’s exact test.
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Sex
a Overall morbidity
Odds ratio
Age
BMI
Co-morbidity
PVE
Preoperative CTx
Resection type
Pringle manoeuvre
Blood transfusion
Severe SD
Severe steatosis
Steatohepatitis
0·1 1 10
*
*
*
b Liver surgery-specific complications
Odds ratio
0·1 1 10
*
*
*
*
*
*
*
Odds ratio
c Major morbidity
0·1 1 10
*
*
Fig. 2 Multivariable analysis of influence of liver injury on short-term postoperative outcomes: a overall morbidity, b liver
surgery-specific complications and c major morbidity. Odds ratios are shown with 95 per cent confidence intervals. PVE, portal vein
embolization; CTx, chemotherapy; SD, sinusoidal dilatation. *P < 0⋅050
Table 3 Univariable analyses of factors influencing short-term postoperative outcome
Postoperative liver failure (n=24) Mortality (n=8)
Odds ratio P Odds ratio P
Sex (F) 0⋅65 (0⋅25, 1⋅68) 0⋅376 0⋅50 (0⋅10, 2⋅25) 0⋅408
Age (years) 1⋅00 (0⋅96, 1⋅04) 0⋅937 1⋅03 (0⋅96, 1⋅05) 0⋅402
BMI (kg/m2) 0⋅90 (0⋅80, 1⋅01) 0⋅070 0⋅96 (0⋅80, 1⋅14) 0⋅630
Co-morbidity 1⋅28 (0⋅53, 3⋅13) 0⋅583 7⋅84 (0⋅92, 66⋅65) 0⋅059
PVE 2⋅62 (0⋅95, 7⋅26) 0⋅064 1⋅09 (0⋅13, 9⋅09) 0⋅938
Preoperative chemotherapy 2⋅41 (0⋅30, 19⋅32) 0⋅409 1⋅51 (0⋅52, 4⋅42) 0⋅702
Resection type (major) –* –* 6⋅56 (0⋅77, 55⋅90) 0⋅085
Pringle manoeuvre 1⋅45 (0⋅57, 3⋅72) 0⋅437 1⋅91 (0⋅43, 8⋅54) 0⋅399
Blood transfusion 4⋅47 (1⋅69, 11⋅82) 0⋅003 14⋅00 (2⋅74, 71⋅51) 0⋅002
Severe SD 3⋅06 (1⋅18, 7⋅92) 0⋅021 2⋅79 (0⋅68, 11⋅44) 0⋅155
Severe steatosis 0⋅47 (0⋅06, 3⋅77) 0⋅473 0⋅86 (0⋅10, 7⋅09) 0⋅887
Steatohepatitis 1⋅90 (0⋅31, 22⋅83) 0⋅492 2⋅71 (0⋅57, 12⋅87) 0⋅210
Values in parentheses are 95 per cent confidence intervals. PVE, portal vein embolization; SD, sinusoidal dilatation. Multiple imputations were used for
univariable analysis. *All patients with liver failure underwent major hepatectomy and none had minor hepatectomy (P < 0⋅001, Fisher’s exact test).
surgery-specific complications and major morbidity is
shown in Fig. 2 and Table S6 (supporting information).
Severe SD was significantly associated with increased
major morbidity only (OR 1⋅73, 95 per cent c.i. 1⋅02 to
2⋅95; P = 0⋅043). Severe steatosis was not significantly
associated with the occurrence of postoperative over-
all or major morbidity, but was related to a decreased
occurrence of liver surgery-specific complications (OR
0⋅52, 0⋅27 to 1⋅00; P= 0⋅049). In contrast, patients with
steatohepatitis showed a significantly increased rate of
postoperative liver surgery-specific complications (OR
2⋅08, 1⋅18 to 3⋅66; P= 0⋅012), and a trend towards
increased overall morbidity (OR 1⋅58, 0⋅99 to 2⋅52;
P= 0⋅057).
Table 3 summarizes the effects of several factors associ-
ated with postoperative liver failure and mortality. Because
of the small number of events, multivariable logistic
regression was not performed. Postoperative liver fail-
ure occurred in 24 of 779 patients (3⋅1 per cent) in the
study cohort (Table 2), seven women and 17 men, with a
median age of 61 (range 48–75) years. All patients with
liver failure had undergone major hepatectomy. The only
factors strongly associated with increased liver failure in
univariable analysis were severe SD (OR 3⋅06, 1⋅18 to
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Sex
Age
BMI
Co-morbidity
5-FU
Capecitabine
Oxaliplatin
Bevacizumab
Cetuximab
Irinotecan
Severe steatosis
Severe SD
Steatohepatitis
0.1 1
Odds ratio
a  Severe sinusoidal dilatation b  Severe steatosis c  Steatohepatitis
Odds ratioOdds ratio
10 0.1 1 10 100 0.1 1 10 100
PVE
*
*
*
*
*
*
*
Fig. 3 Multivariable analysis of influence of risk factors on liver injury: a severe sinusoidal dilatation, b severe steatosis and c
steatohepatitis. Odds ratios are shown with 95 per cent confidence intervals. PVE, portal vein embolization; 5-FU, 5-fluorouracil.
*P < 0⋅050
7⋅92; P= 0⋅021) and perioperative blood transfusion (OR
4⋅47, 1⋅69 to 11⋅82; P= 0⋅003).
In total, eight patients (1⋅0 per cent) died in the peri-
operative period after liver resection, seven within 90 days
and one at 101 days during the hospital stay. The six men
and two women had a median age of 64 (range 48–75)
years. Perioperative blood transfusion (OR 14⋅00, 2⋅74 to
71⋅51; P= 0⋅002) was the sole factor related to increased
mortality in univariable analysis. A trend was found for
major liver resection (OR 6⋅56, 0⋅77 to 55⋅90; P= 0⋅085)
and preoperative co-morbidity (OR 7⋅84, 0⋅92 to 66⋅65;
P= 0⋅059) to be associated with increased postoperative
mortality. Severe SD (OR 2⋅79, 0⋅68 to 11⋅44; P= 0⋅155),
severe steatosis (OR 0⋅86, 0⋅10 to 7⋅09; P= 0⋅887) and
steatohepatitis (OR 2⋅71, 0⋅57 to 12⋅87; P= 0⋅210) were
not related to postoperative mortality.
Because steatohepatitis, but not severe steatosis, neg-
atively affected postoperative short-term outcomes,
lobular inflammation and hepatocellular ballooning were
considered key factors for poor outcome. A subgroup anal-
ysis supported this hypothesis. In multivariable analyses,
severe (grade 2–3) lobular inflammation was associ-
ated with increased overall postoperative morbidity (OR
2⋅22, 1⋅48 to 3⋅34; P= 0⋅001) and liver surgery-specific
morbidity (OR 3⋅35, 2⋅11 to 5⋅32; P < 0⋅001), but not
major morbidity (OR 1⋅63, 0⋅85 to 3⋅10; P= 0⋅138). In
contrast, neither severe steatosis (over 33 per cent) nor
the presence of hepatocellular ballooning (grade 1–2)
was associated with an increased complication rate in all
multivariable analyses.
Associations between several preoperative variables
and the occurrence of severe SD, severe steatosis and
steatohepatitis are summarized in Fig. 3 and Table S7 (sup-
porting information). Oxaliplatin (OR 2⋅74, 1⋅67 to 4⋅49;
P < 0⋅001) was related to increased occurrence of severe
SD in multivariable analysis, whereas the addition of beva-
cizumab was associated with a twofold decrease in severe
SD in patients who received oxaliplatin (OR 0⋅50, 0⋅30 to
0⋅82; P= 0⋅006) when the analysis was adjusted solely by
database source. Patients with severe steatosis showed a
decreased incidence of severe SD (OR 0⋅44, 0⋅24 to 0⋅83;
P= 0⋅011) and vice versa (OR 0⋅36, 0⋅15 to 0⋅88; P= 0⋅025).
BMI was related to an increase in severe steatosis (OR
1⋅15, 1⋅08 to 1⋅21; P < 0⋅001), whereas the incidence of
severe steatosis was decreased in patients with portal vein
embolization (PVE) (OR 0⋅29, 0⋅08 to 1⋅00; P= 0⋅050).
Only severe steatosis was significantly associated with an
increased occurrence of steatohepatitis (OR 15⋅09, 6⋅25 to
36⋅45; P < 0⋅001).
Discussion
In this study, an increase in postoperative major morbid-
ity and liver surgery-specific complications after partial
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hepatectomy was observed in patients with severe SD and
steatohepatitis respectively, whereas severe steatosis was
associated with a decreased occurrence of liver surgery-
specific complications. Postoperative liver failure occurred
more often in patients with severe SD. With respect
to steatohepatitis, lobular inflammation, but not severe
steatosis or hepatocellular ballooning, was strongly linked
to increased postoperative morbidity. Oxaliplatin-based
chemotherapy was independently associated with an
increase in the occurrence of severe SD, whereas a decrease
was seen with the addition of bevacizumab. An inverse
relationship was found between severe SD and severe
steatosis.
Mechanisms underlying the negative influence of severe
SD on major morbidity are unknown, although preopera-
tive hepatic dysfunction, impairment of liver regeneration,
Kupffer cell dysfunction, enhanced blood loss due to haem-
orrhagic pools, fragility of the liver, and increased hepa-
tocellular necrosis as seen in human and animal models,
can all be reasons for poor liver function and an increased
complication rate after severe SD45,46. However, as the P
value was of borderline significance, the effect of severe
SD on major morbidity must be interpreted with caution.
The progression of steatohepatitis is estimated by the
so-called NAS, which is composed of scores for steatosis,
lobular inflammation and hepatocellular ballooning27.
Multivariable subgroup analyses examining the influence
of these separate NAS subcategories on postoperative
outcome showed a detrimental influence of lobular
inflammation on all outcomes, whereas severe steatosis and
hepatocellular ballooning had no effect. The mechanism
behind steatohepatitis being a determinant of postoperative
short-term outcomes is uncertain. Electron microscopy
revealed that mitochondrial structural defects in hepato-
cytes correlate with steatohepatitis, but not with steatosis47.
Moreover, the ability of the liver to recover from adenosine
5′-triphosphate depletion was severely impaired48, liver
regeneration was diminished49, and humoral and cellular
immune responses to enhanced oxidative stress were found
in patients with steatohepatitis. These factors may account
for postoperative complications.
Severe steatosis did not significantly influence short-term
overall morbidity, major morbidity or mortality after par-
tial hepatectomy in this study, which is in line with previous
reports50,51, but in contrast to findings in other studies52,53.
Patients with severe steatosis even showed a decreased
occurrence of liver surgery-specific complications. This
might be explained by surgeons being more careful during
surgery when observing a severely steatotic (‘yellow’) liver.
However, with a P value of 0⋅049, this evidence needs to be
validated by future research.
Severe SD was more common in patients who received
oxaliplatin than among those who did not (29⋅6 versus
14⋅0 per cent). This is in line with previous studies10,17
that showed a similarly high rate of severe SD after
oxaliplatin-based regimens. The addition of bevacizumab,
an angiogenesis inhibitor, to oxaliplatin-based chemo-
therapy has been associated with a decreased incidence
of SD44. Indeed, when the analysis was restricted to
the population that received oxaliplatin-based treatment,
bevacizumab was associated with a greatly decreased occur-
rence of severe SD. Although mechanisms underpinning
those observations remain unclear, activation of vascular
endothelial growth factor and coagulation pathways in
oxaliplatin-related SD might be involved54.
Importantly, severe steatosis was linked to a decreased
occurrence of severe SD and vice versa, raising the pos-
sibility that these events are mutually exclusive. Several
phenomena could underlie this observation. First, mechan-
ical pressure exerted by fat-laden, swollen hepatocytes
may distort the hepatic microvasculature. In mice with
severe steatosis, a decrease in sinusoidal perfusion, loss
of fenestrae and narrowing of the sinusoidal lumen were
observed55. SD may therefore not develop owing to spatial
constraints. Conversely, atrophied hepatocellular plates in
severe SD may render these hepatocytes incapable of fatty
acid uptake. Alternatively, histological assessment may be
more challenging in a liver affected by both severe SD and
steatosis, increasing the likelihood of misclassification of
either one of these injury types. However, several patholo-
gists with hepatobiliary expertise independently considered
this probability very small. Although the reduction in SD in
patients with severe steatosis is interesting, central pathol-
ogy review is needed to verify this finding.
Apart from oxaliplatin, preoperative PVE was marginally
associated with an increased occurrence of severe SD.
A previous study56 has already acknowledged a possible
influence of PVE on the development of vascular injury,
probably by induction of ischaemia. The present authors
hypothesize that the hepatic artery buffer response after
PVE might play an even more profound role, as shown
by the induction of microvascular remodelling and SD in
the embolized lobe after portal branch ligation in a rodent
model57. However, the morphology of the non-embolized
remnant lobe may differ from that of the resected lobe, and
liver histology and function may therefore not be affected
after resection58.
In the present study, severe SD was less common in
patients receiving additional bevacizumab than among
those receiving oxaliplatin alone. Severe SD was shown to
be associated with an increased major complication rate
and vice versa. Although the effect of co-administration of
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oxaliplatin with bevacizumab on surgical outcome could
not be investigated directly here, adding bevacizumab
might provide an advantageous effect on postoperative out-
come in patients treated with oxaliplatin.
Parenchymal damage due to chemotherapy can be diag-
nosed before surgery by radiological and biochemical
means, as reviewed recently in detail59. Despite (exper-
imental) research focusing on CALI, little evidence is
available for its treatment in the human setting59. When
liver injury is confirmed before operation, surgeons are
thus advised to adapt surgical management to prevent com-
plications. In the present study, the transfusion of packed
red blood cells was associated with an increased postoper-
ative complication rate, in line with previous literature60.
Central venous pressure should be low during surgery to
prevent excessive blood loss. Moreover, major hepatec-
tomy was confirmed to be associated with an increased
postoperative complication rate, which encourages min-
imization of the resection volume. Performing wedge
resections instead of hemihepatectomy, and the use of
radiofrequency ablation might be beneficial when feasible.
This study demonstrated both the effect of chemother-
apy on liver injury and the subsequent effect of liver injury
on short-term postoperative outcome in a large multicen-
tre patient cohort. However, some limitations of the study
should be discussed. First, NRH has recently caused con-
cern because of its relationship to increased postoperative
morbidity11. Although analysis of the effect of NRH on
postoperative outcome would have been of interest, this
was not possible owing to lack of available data. This may
be because the data used in this review were from stud-
ies published before or around 2013, when NRH had not
yet gained the attention it deserves. Inclusion of NRH
is recommended when exploring the relationship between
CALI and postoperative outcomes in future studies. Next,
data on the interval between cessation of chemotherapy
and partial hepatectomy, as well as the number of cycles
administered, were not available for every study cohort.
Therefore, the influence of these factors on the occur-
rence of CALI and short-term complications could not be
evaluated. In addition, central review of all histopathol-
ogy slides would have strengthened the paper substantially.
Unfortunately, this was not feasible for logistical reasons.
It must be highlighted, nonetheless, that all sections were
reviewed by local pathologists with hepatobiliary exper-
tise, and assessed according to uniform, well established
and globally accepted scoring systems for SD, steatosis
and steatohepatitis. Finally, as no RCTs exist on the topic,
mainly retrospective cohort studies were included in this
review. Despite this limitation, all included studies had
a low risk of bias and nearly all original data could be
retained, making this the most comprehensive multicentre
data set currently available.
Considering the negative relationship between CALI
and postoperative morbidity, it is advised to adapt sur-
gical management when CALI is diagnosed. Moreover,
with decreased chemotherapy responsiveness28,61, short-
ened overall survival62 and increasing doubts about the
usefulness of neoadjuvant chemotherapy in certain patient
groups63, it could even be speculated that some patients
would benefit from immediate resection instead of neo-
adjuvant chemotherapy. Prospective registration such as
the ALPPS (Associated Liver Partition and Portal vein Lig-
ation for Staged hepatectomy) Registry64 provides a way to
obtain a higher level of evidence on this topic.
Collaborators
Other members of the CALI consortium are: I. García Sanz, E. Martín
Pérez (Hepatopancreaticobiliary Surgery Unit, Department of Surgery,
Hospital Universitario de la Princesa, Madrid, Spain); J. Y. Cho, Y. R. Choi
(Department of Surgery, Seoul National University Bundang Hospital,
Seoul National College of Medicine, Seongnam, Korea); W. Phillips,
M. Michael (Division of Cancer Surgery, Peter MacCallum Cancer
Centre, Department of Surgery, University of Melbourne, St Vincent’s
Hospital, Melbourne, Victoria, Australia); F. Panaro (Digestive Surgery
and Transplantation, Hôpital de Hautepierre, University Hospital of
Strasbourg, University of Strasbourg, Strasbourg, France); M.-P. Chenard
(Department of Pathology, Hôpital de Hautepierre, University Hospital
of Strasbourg, University of Strasbourg, Strasbourg, France); C. Verhoef,
D. J. Grünhagen (Department of Surgical Oncology, Erasmus MC Cancer
Institute, Rotterdam, The Netherlands); J. Vara (Digestive Tumours
Unit, Institut Bergonié, Bordeaux, France); O. Scatton (Department of
Digestive and Hepatobiliary Surgery, La Pitié Hospital, Université Pierre
et Marie Curie, Paris, France); T. Hashimoto, M. Makuuchi (Department
of Hepatopancreaticobiliary Surgery, Japanese Red Cross Medical Centre,
Tokyo, Japan); G. De Rosa, N. Ravarino (Department of Pathology,
Mauriziano Umberto I Hospital, Turin, Italy).
Acknowledgements
J.Z. and K.M.C.v.M. contributed equally to this study.
The authors thank H. Nguyen for thorough reading and
commenting on the manuscript. J.Z. is supported by the
China Scholarship Council (201207040056).
Disclosure: The authors declare no conflict of interest.
References
1 Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C,
Rebelo M et al. Cancer incidence and mortality worldwide:
sources, methods and major patterns in GLOBOCAN 2012.
Int J Cancer 2015; 136: E359–E386.
2 Leonard GD, Brenner B, Kemeny NE. Neoadjuvant
chemotherapy before liver resection for patients with
unresectable liver metastases from colorectal carcinoma.
J Clin Oncol 2005; 23: 2038–2048.
© 2017 BJS Society Ltd www.bjs.co.uk BJS 2017; 104: 990–1002
Published by John Wiley & Sons Ltd
1000 J. Zhao, K. M. C. van Mierlo, J. Gómez-Ramírez, H. Kim, C. H. C. Pilgrim, P. Pessaux et al.
3 Kanas GP, Taylor A, Primrose JN, Langeberg WJ, Kelsh
MA, Mowat FS et al. Survival after liver resection in
metastatic colorectal cancer: review and meta-analysis of
prognostic factors. Clin Epidemiol 2012; 4: 283–301.
4 Scheele J. Hepatectomy for liver metastases. Br J Surg 1993;
80: 274–276.
5 Tanaka K, Adam R, Shimada H, Azoulay D, Lévi F, Bismuth
H. Role of neoadjuvant chemotherapy in the treatment of
multiple colorectal metastases to the liver. Br J Surg 2003;
90: 963–969.
6 Adam R, Wicherts DA, de Haas RJ, Ciacio O, Lévi F, Paule
B et al. Patients with initially unresectable colorectal liver
metastases: is there a possibility of cure? J Clin Oncol 2009;
27: 1829–1835.
7 Nordlinger B, Van Cutsem E, Rougier P, Köhne CH,
Ychou M, Sobrero A et al.; European Colorectal Metastases
Treatment Group. Does chemotherapy prior to liver
resection increase the potential for cure in patients with
metastatic colorectal cancer? A report from the European
Colorectal Metastases Treatment Group. Eur J Cancer 2007;
43: 2037–2045.
8 Robinson SM, Wilson CH, Burt AD, Manas DM, White
SA. Chemotherapy-associated liver injury in patients with
colorectal liver metastases: a systematic review and
meta-analysis. Ann Surg Oncol 2012; 19: 4287–4299.
9 Zorzi D, Laurent A, Pawlik TM, Lauwers GY, Vauthey JN,
Abdalla EK. Chemotherapy-associated hepatotoxicity and
surgery for colorectal liver metastases. Br J Surg 2007; 94:
274–286.
10 Rubbia-Brandt L, Lauwers GY, Wang H, Majno PE,
Tanabe K, Zhu AX et al. Sinusoidal obstruction syndrome
and nodular regenerative hyperplasia are frequent
oxaliplatin-associated liver lesions and partially prevented by
bevacizumab in patients with hepatic colorectal metastasis.
Histopathology 2010; 56: 430–439.
11 Viganò L, Rubbia-Brandt L, De Rosa G, Majno P, Langella
S, Toso C et al. Nodular regenerative hyperplasia in patients
undergoing liver resection for colorectal metastases after
chemotherapy: risk factors, preoperative assessment and
clinical impact. Ann Surg Oncol 2015; 22: 4149–4157.
12 Ribero D, Wang H, Donadon M, Zorzi D, Thomas MB,
Eng C et al. Bevacizumab improves pathologic response and
protects against hepatic injury in patients treated with
oxaliplatin-based chemotherapy for colorectal liver
metastases. Cancer 2007; 110: 2761–2767.
13 Vauthey JN, Pawlik TM, Ribero D, Wu TT, Zorzi D, Hoff
PM et al. Chemotherapy regimen predicts steatohepatitis
and an increase in 90-day mortality after surgery for hepatic
colorectal metastases. J Clin Oncol 2006; 24: 2065–2072.
14 Khan AZ, Morris-Stiff G, Makuuchi M. Patterns of
chemotherapy-induced hepatic injury and their implications
for patients undergoing liver resection for colorectal liver
metastases. J Hepatobiliary Pancreat Surg 2009; 16: 137–144.
15 Nakano H, Oussoultzoglou E, Rosso E, Casnedi S,
Chenard-Neu MP, Dufour P et al. Sinusoidal injury
increases morbidity after major hepatectomy in patients with
colorectal liver metastases receiving preoperative
chemotherapy. Ann Surg 2008; 247: 118–124.
16 Pilgrim CH, Satgunaseelan L, Pham A, Murray W, Link E,
Smith M et al. Correlations between histopathological
diagnosis of chemotherapy-induced hepatic injury, clinical
features, and perioperative morbidity. HPB 2012; 14:
333–340.
17 Viganò L, Ravarino N, Ferrero A, Motta M, Torchio B,
Capussotti L. Prospective evaluation of accuracy of liver
biopsy findings in the identification of chemotherapy-
associated liver injuries. Arch Surg 2012; 147: 1085–1091.
18 Aloia T, Sebagh M, Plasse M, Karam V, Lévi F, Giacchetti S
et al. Liver histology and surgical outcomes after
preoperative chemotherapy with fluorouracil plus oxaliplatin
in colorectal cancer liver metastases. J Clin Oncol 2006; 24:
4983–4990.
19 Komori H, Beppu T, Baba Y, Horino K, Imsung C, Masuda
T et al. Histological liver injury and surgical outcome after
FOLFOX followed by a hepatectomy for colorectal liver
metastases in Japanese patients. Int J Clin Oncol 2010; 15:
263–270.
20 Pawlik TM, Olino K, Gleisner AL, Torbenson M, Schulick
R, Choti MA. Preoperative chemotherapy for colorectal
liver metastases: impact on hepatic histology and
postoperative outcome. J Gastrointest Surg 2007; 11:
860–868.
21 Sahajpal A, Vollmer CM, Dixon E, Chan EK, Wei A, Cattral
MS et al. Chemotherapy for colorectal cancer prior to liver
resection for colorectal cancer hepatic metastases does not
adversely affect peri-operative outcomes. J Surg Oncol 2007;
95: 22–27.
22 Makowiec F, Möhrle S, Neeff H, Drognitz O, Illerhaus G,
Opitz OG et al. Chemotherapy, liver injury, and
postoperative complications in colorectal liver metastases.
J Gastrointest Surg 2011; 15: 153–164.
23 Kandutsch S, Klinger M, Hacker S, Wrba F, Gruenberger
B, Gruenberger T. Patterns of hepatotoxicity after
chemotherapy for colorectal cancer liver metastases. Eur J
Surg Oncol 2008; 34: 1231–1236.
24 Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA
Group. Preferred reporting items for systematic reviews and
meta-analyses: the PRISMA statement. Ann Intern Med
2009; 151: 264–269, W264.
25 Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD,
Rennie D et al. Meta-analysis of observational studies in
epidemiology: a proposal for reporting. Meta-analysis Of
Observational Studies in Epidemiology (MOOSE) group.
JAMA 2000; 283: 2008–2012.
26 Rubbia-Brandt L, Audard V, Sartoretti P, Roth AD,
Brezault C, Le Charpentier M et al. Severe hepatic
sinusoidal obstruction associated with oxaliplatin-based
chemotherapy in patients with metastatic colorectal cancer.
Ann Oncol 2004; 15: 460–466.
27 Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos
MJ, Cummings OW et al. Design and validation of a
© 2017 BJS Society Ltd www.bjs.co.uk BJS 2017; 104: 990–1002
Published by John Wiley & Sons Ltd
Impact of chemotherapy-associated liver injury on outcome after partial hepatectomy 1001
histological scoring system for nonalcoholic fatty liver
disease. Hepatology 2005; 41: 1313–1321.
28 Vreuls CP, Van Den Broek MA, Winstanley A, Koek GH,
Wisse E, Dejong CH et al. Hepatic sinusoidal obstruction
syndrome (SOS) reduces the effect of oxaliplatin in
colorectal liver metastases. Histopathology 2012; 61: 314–318.
29 van Mierlo KMC, Zhao J, Kleijnen J, Rensen SS, Schaap
FG, Dejong CHC et al. The influence of chemotherapy-
associated sinusoidal dilatation on short-term outcome after
partial hepatectomy for colorectal liver metastases: a
systematic review with meta-analysis. Surg Oncol 2016; 25:
298–307.
30 Brunt EM, Kleiner DE, Wilson LA, Belt P,
Neuschwander-Tetri BA; NASH Clinical Research Network
(CRN). Nonalcoholic fatty liver disease (NAFLD) activity
score and the histopathologic diagnosis in NAFLD: distinct
clinicopathologic meanings. Hepatology 2011; 53: 810–820.
31 Dindo D, Demartines N, Clavien PA. Classification of
surgical complications: a new proposal with evaluation in a
cohort of 6336 patients and results of a survey. Ann Surg
2004; 240: 205–213.
32 van den Broek MA, van Dam RM, van Breukelen GJ,
Bemelmans MH, Oussoultzoglou E, Pessaux P et al.
Development of a composite endpoint for randomized
controlled trials in liver surgery. Br J Surg 2011; 98:
1138–1145.
33 Balzan S, Belghiti J, Farges O, Ogata S, Sauvanet A,
Delefosse D et al. The ‘50–50 criteria’ on postoperative day
5: an accurate predictor of liver failure and death after
hepatectomy. Ann Surg 2005; 242: 824–828.
34 Couinaud C. Liver anatomy: portal (and suprahepatic) or
biliary segmentation. Dig Surg 1999; 16: 459–467.
35 Hayden JA, van der Windt DA, Cartwright JL, Côté P,
Bombardier C. Assessing bias in studies of prognostic
factors. Ann Intern Med 2013; 158: 280–286.
36 Hayden JA, Côté P, Bombardier C. Evaluation of the quality
of prognosis studies in systematic reviews. Ann Intern Med
2006; 144: 427–437.
37 Debray TP, Moons KG, Abo-Zaid GM, Koffijberg H, Riley
RD. Individual participant data meta-analysis for a binary
outcome: one-stage or two-stage? PLoS One 2013; 8: e60650.
38 Abo-Zaid G, Guo B, Deeks JJ, Debray TP, Steyerberg EW,
Moons KG et al. Individual participant data meta-analyses
should not ignore clustering. J Clin Epidemiol 2013; 66:
865–873.e864.
39 Gómez-Ramírez J, Martín-Pérez E, Amat CG, Sanz IG,
Bermejo E, Rodríguez A et al. Influence of pre-surgical
chemotherapy on liver parenchyma and post-surgical
outcome of patients subjected to hepatectomy due to
colorectal carcinoma metastases. Cir Esp 2010; 88: 404–412.
40 Nam SJ, Cho JY, Lee HS, Choe G, Jang JJ, Yoon YS et al.
Chemotherapy-associated hepatopathy in Korean colorectal
cancer liver metastasis patients: oxaliplatin-based
chemotherapy and sinusoidal injury. Korean J Pathol 2012;
46: 22–29.
41 Pessaux P, Marzano E, Casnedi S, Bachellier P, Jaeck D,
Chenard MP. Histological and immediate postoperative
outcome after preoperative cetuximab: case-matched control
study. World J Surg 2010; 34: 2765–2772.
42 Soubrane O, Brouquet A, Zalinski S, Terris B, Brézault C,
Mallet V et al. Predicting high grade lesions of sinusoidal
obstruction syndrome related to oxaliplatin-based
chemotherapy for colorectal liver metastases: correlation
with post-hepatectomy outcome. Ann Surg 2010; 251:
454–460.
43 Takamoto T, Hashimoto T, Sano K, Maruyama Y, Inoue K,
Ogata S et al. Recovery of liver function after the cessation
of preoperative chemotherapy for colorectal liver metastasis.
Ann Surg Oncol 2010; 17: 2747–2755.
44 van der Pool AE, Marsman HA, Verheij J, Ten Kate FJ,
Eggermont AM, Ijzermans JN et al. Effect of bevacizumab
added preoperatively to oxaliplatin on liver injury and
complications after resection of colorectal liver metastases.
J Surg Oncol 2012; 106: 892–897.
45 Schiffer E, Frossard JL, Rubbia-Brandt L, Mentha G, Pastor
CM. Hepatic regeneration is decreased in a rat model of
sinusoidal obstruction syndrome. J Surg Oncol 2009; 99:
439–446.
46 Hubert C, Dahrenmoller C, Marique L, Jabbour N,
Gianello P, Leclercq I. Hepatic regeneration in a rat model
is impaired by chemotherapy agents used in metastatic
colorectal cancer. Eur J Surg Oncol 2015; 41: 1471–1478.
47 Sanyal AJ, Campbell-Sargent C, Mirshahi F, Rizzo WB,
Contos MJ, Sterling RK et al. Nonalcoholic steatohepatitis:
association of insulin resistance and mitochondrial
abnormalities. Gastroenterology 2001; 120: 1183–1192.
48 Cortez-Pinto H, Chatham J, Chacko VP, Arnold C, Rashid
A, Diehl AM. Alterations in liver ATP homeostasis in
human nonalcoholic steatohepatitis: a pilot study. JAMA
1999; 282: 1659–1664.
49 Yang SQ, Lin HZ, Mandal AK, Huang J, Diehl AM.
Disrupted signaling and inhibited regeneration in obese
mice with fatty livers: implications for nonalcoholic fatty
liver disease pathophysiology. Hepatology 2001; 34:
694–706.
50 Wiggans MG, Lordan JT, Shahtahmassebi G, Aroori S,
Bowles MJ, Stell DA. The interaction between diabetes,
body mass index, hepatic steatosis, and risk of liver resection:
insulin dependent diabetes is the greatest risk for major
complications. HPB Surg 2014; 2014: 586159.
51 Reddy SK, Marsh JW, Varley PR, Mock BK, Chopra KB,
Geller DA et al. Underlying steatohepatitis, but not simple
hepatic steatosis, increases morbidity after liver resection: a
case–control study. Hepatology 2012; 56: 2221–2230.
52 McCormack L, Petrowsky H, Jochum W, Furrer K,
Clavien PA. Hepatic steatosis is a risk factor for
postoperative complications after major hepatectomy: a
matched case–control study. Ann Surg 2007; 245:
923–930.
53 Kooby DA, Fong Y, Suriawinata A, Gonen M, Allen PJ,
Klimstra DS et al. Impact of steatosis on perioperative
© 2017 BJS Society Ltd www.bjs.co.uk BJS 2017; 104: 990–1002
Published by John Wiley & Sons Ltd
1002 J. Zhao, K. M. C. van Mierlo, J. Gómez-Ramírez, H. Kim, C. H. C. Pilgrim, P. Pessaux et al.
outcome following hepatic resection. J Gastrointest Surg
2003; 7: 1034–1044.
54 Rubbia-Brandt L, Tauzin S, Brezault C, Delucinge-Vivier
C, Descombes P, Dousset B et al. Gene expression profiling
provides insights into pathways of oxaliplatin-related
sinusoidal obstruction syndrome in humans. Mol Cancer
Ther 2011; 10: 687–696.
55 Farrell GC, Teoh NC, McCuskey RS. Hepatic
microcirculation in fatty liver disease. Anat Rec (Hoboken)
2008; 291: 684–692.
56 Brouquet A, Benoist S, Julie C, Penna C, Beauchet A,
Rougier P et al. Risk factors for chemotherapy-associated
liver injuries: a multivariate analysis of a group of 146
patients with colorectal metastases. Surgery 2009; 145:
362–371.
57 Kollmar O, Corsten M, Scheuer C, Vollmar B, Schilling
MK, Menger MD. Portal branch ligation induces a hepatic
arterial buffer response, microvascular remodeling,
normoxygenation, and cell proliferation in portal
blood-deprived liver tissue. Am J Physiol Gastrointest Liver
Physiol 2007; 292: 1534–1542.
58 Matsuo K, Murakami T, Kawaguchi D, Hiroshima Y, Koda
K, Yamazaki K et al. Histologic features after surgery
associating liver partition and portal vein ligation for staged
hepatectomy versus those after hepatectomy with portal vein
embolization. Surgery 2016; 159: 1289–1298.
59 van Mierlo KM, Schaap FG, Dejong CH, Olde Damink
SW. Liver resection for cancer: new developments in
prediction, prevention and management of postresectional
liver failure. J Hepatol 2016; 65: 1217–1231.
60 Farid SG, White A, Khan N, Toogood GJ, Prasad KR,
Lodge JP. Clinical outcomes of left hepatic trisectionectomy
for hepatobiliary malignancy. Br J Surg 2016; 103:
249–256.
61 Viganò L, Capussotti L, De Rosa G, De Saussure WO,
Mentha G, Rubbia-Brandt L. Liver resection for
colorectal metastases after chemotherapy: impact of
chemotherapy-related liver injuries, pathological tumor
response, and micrometastases on long-term survival. Ann
Surg 2013; 258: 731–742.
62 Tamandl D, Klinger M, Eipeldauer S, Herberger B,
Kaczirek K, Gruenberger B et al. Sinusoidal obstruction
syndrome impairs long-term outcome of colorectal liver
metastases treated with resection after neoadjuvant
chemotherapy. Ann Surg Oncol 2011; 18: 421–430.
63 Khoo E, O’Neill S, Brown E, Wigmore SJ, Harrison EM.
Systematic review of systemic adjuvant, neoadjuvant and
perioperative chemotherapy for resectable colorectal-liver
metastases. HPB 2016; 18: 485–493.
64 Schadde E, Ardiles V, Robles-Campos R, Malago M,
Machado M, Hernandez-Alejandro R et al.; ALPPS Registry
Group. Early survival and safety of ALPPS: first report of
the International ALPPS Registry. Ann Surg 2014; 260:
829–836.
Supporting information
Additional supporting information may be found in the online version of this article:
Appendix S1 Study protocol (Word document)
Table S1 Search strategy (Word document)
Table S2 Inclusion criteria (Word document)
Table S3 Variables in multiple imputations (Word document)
Table S4 Quality in Prognostic Studies detailed risk-of-bias assessment of individual included studies (Word
document)
Table S5 Relationship between non-alcoholic fatty liver disease activity score and lobular inflammation (Word
document)
Table S6 Influence of liver injury on short-term postoperative outcomes (Word document)
Table S7 Factors related to liver injury (Word document)
Fig. S1 Flow chart summarizing final inclusion process (Word document)
© 2017 BJS Society Ltd www.bjs.co.uk BJS 2017; 104: 990–1002
Published by John Wiley & Sons Ltd
